Who Are the Core Customers in Thermo Fisher Scientific Company's Target Market?

Thermo Fisher Scientific customers center on Biopharmaceutical companies that account for roughly 56 percent of 2025 revenue; the firm targets Big Pharma for global commercial manufacturing scale and Emerging Biotech for outsourced R&D and clinical-trial support.

Laboratories and research institutions – Academic research centers and government labs – make up about 15 percent of revenue, buying high-end instruments for fundamental research; Healthcare and clinical labs plus Industrial and environmental testing labs fill the remaining 29 percent across diagnostics, forensic, and environmental monitoring use cases.

Thermo Fisher serves a mixed customer base: institutional and commercial buyers. Decision makers include procurement departments that purchase Thermo Fisher equipment, lab directors at research labs that use Thermo Fisher instruments, and clinical laboratory managers in hospital laboratories as Thermo Fisher clients.

Biopharmaceutical companies are the most important segment by revenue and strategic relevance; they drive recurring sales of reagents, instruments, and outsourced services and account for the largest share of Thermo Fisher Scientific customers and commercial buyers of Thermo Fisher lab equipment.

North America drives the largest share of Thermo Fisher Scientific customers, led by hospitals, clinical laboratories, and biopharmaceutical companies; demand is anchored in large procurement departments purchasing instruments, reagents, and consumables.

Europe accounts for roughly 25 percent of revenue with strong academic research centers and industrial testing labs; Asia-Pacific, especially China, is the fastest-growing market as local biomanufacturing and biotech startups scale.

Thermo Fisher Scientific is strongest in supplying laboratories and research institutions with end-to-end solutions – high-volume consumables, bioprocessing equipment, and clinical diagnostics platforms – driving steady recurring revenue and cross-sell opportunities.

Demand is surging for tools used in GLP-1 agonist production and mRNA-based therapies, plus next-generation sequencing and advanced mass spectrometry as health systems move toward precision medicine; Asia-Pacific shows the highest CAGR in procurement for these categories. Read more on ownership and control Ownership and Control of Thermo Fisher Scientific Company.

Thermo Fisher Scientific customers expand as the firm cross-sells consumables and services to laboratories and research institutions, biopharmaceutical companies, and healthcare and clinical labs, and by integrating specialized diagnostic platforms to address clinical laboratories as Thermo Fisher clients and biotech startups purchasing Thermo Fisher reagents.

Retention relies on the razor-and-blade model where consumables and service contracts – now nearly 80 percent of revenue – create recurring procurement flows for research labs that use Thermo Fisher instruments and procurement departments that purchase Thermo Fisher equipment.

Loyalty is cemented through installed-instrument ecosystems, long-term service agreements, reagent and consumable renewals, and customer success programs for academic research centers and hospital laboratories procurement Thermo Fisher – driving high customer depth and repeat purchases.

The top growth lever is consumables recurring revenue plus targeted M&A that fills portfolio gaps; with R&D spend at $1.5 billion annually and consumables at ~80 percent of revenue, Thermo Fisher is positioned to capture mid-single-digit organic growth as biotech funding and biologic drug manufacturing recover in 2026. Read more in the company overview: Mission, Vision, and Values of Thermo Fisher Scientific Company